ProfileGDS5678 / 1459636_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 56% 55% 56% 56% 58% 56% 55% 55% 53% 55% 56% 55% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6316160
GSM967853U87-EV human glioblastoma xenograft - Control 23.3979956
GSM967854U87-EV human glioblastoma xenograft - Control 33.3849355
GSM967855U87-EV human glioblastoma xenograft - Control 43.3490956
GSM967856U87-EV human glioblastoma xenograft - Control 53.3479856
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5696958
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5000556
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3781555
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3655555
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2745453
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.375755
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3720856
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3947255
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3843955